Cargando…
Administration of a vasoactive intestinal peptide antagonist significantly enhances the autologous anti-leukemia T cell response in a murine model of AML
Autores principales: | Petersen, Christopher, Li, Jian-Ming, Waller, Edmund |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649410/ http://dx.doi.org/10.1186/2051-1426-3-S2-P238 |
Ejemplares similares
-
VIPhyb, an Antagonist of Vasoactive Intestinal Peptide Receptor, Enhances Cellular Antiviral Immunity in Murine Cytomegalovirus Infected Mice
por: Li, Jian-Ming, et al.
Publicado: (2013) -
Vasoactive intestinal peptide inhibits the production of Salmonella-induced inflammatory cytokines by human monocytes
por: Askar, B, et al.
Publicado: (2014) -
Gene Expression Analysis Links Autocrine Vasoactive Intestinal Peptide and ZEB1 in Gastrointestinal Cancers
por: Rao, Ishani H., et al.
Publicado: (2023) -
Significance of gain and loss of chromosomal abnormalities in AML: an Indian experience
por: Trivedi, Pina J, et al.
Publicado: (2014) -
Role of vasoactive intestinal peptide in osteoarthritis
por: Jiang, Wei, et al.
Publicado: (2016)